Experience with intranasal zolmitriptan in cluster headache;Experiencia con zolmitriptan nasal en la cefalea en racimos

Neurologia

Volumn 21, Issue 3, 2006, Pages 131-134

  Pascual, Julio ^a,e   Navarro, A ^b   Caminero, A B ^c   Jurado, C ^d  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Cluster headache; Intranasal zolmitriptan; Subcutaneous sumatriptan

Indexed keywords

SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN; OXAZOLIDINONE DERIVATIVE; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CLUSTER HEADACHE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; ADULT; AGED; CLINICAL TRIAL; FEMALE; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INTRANASAL; ADULT; AGED; CLUSTER HEADACHE; FEMALE; HUMANS; MIDDLE AGED; OXAZOLIDINONES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 33646562171     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kudrow L. Response of cluster headache attacks to oxygen inhalation. Headache 1981;21:1-4.
2. The Sumatriptan Cluster Headache Study Group. Treatment of acute cluster headache with sumatriptan. N Engl J Med 1991;325:322-6.
3. Wilkinson M, Pfaffenrath V, Schoenen J, Diner HC, Steiner TJ. Migraine and cluster headache-their management with sumatriptan: critical review of the current clinical experience. Cephalalgia 1995;15:337-57.
4. Pascual J. Experiencia con sumatriptán subcutáneo en el tratamiento sintomático de la migraña. Neurología 1994;9:282-6.
5. Van Vliet JA, Bahra A, Martín V, Ramadan N, Aurora SK, Mathew NT, et al. Intranasal sumatriptan in cluster headache: randomized placebo-controlled double-blind study. Neurology 2003;60:630-3.
6. Yates R, Nairn K, Dixon R, Kemp JV, Dane AL. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. J Clin Pharmacol 2002;42:1244-50.
7. Yates R, Nairn K, Dixon R, Seaber E. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. Clin Pharmacol 2002;42:1237-43.
8. Wall A, Kagedal M, Nilsson D, Yates R, Langstrom B, Bergstrom M. An open-label positron emission tomography study to investigate the distribution of intranasally administered 11Czolmitriptan into the CSN. Eur J Neurol 2003;10(Suppl. 1):36.
9. Syrett N, Abu-Shakra S, Yates R. Zolmitriptan nasal spray: advances in migraine treatment. Neurology 2003;61(Suppl. 4):27-30.
10. Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Henasen S, Farkkila M. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 2003;17:653-67.
11. Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: randomised, double-blind, placebo-controlled study. CNS Drugs 2005;19:125-36.
12. Gawel M, Aschoff J, May A, Charlesworth BR. REALIZE Study Team. Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine: results from phase 1 of the REALIZE Study. Headache 2005;45:7-16.
13. Dowson AJ, Charlesworth BR, Green J, Farkkila M, Diener HC, Hansen SB, et al. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial. Headache 2005;45:17-24.
14. Dowson AJ, Charlesworth BR, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M. Tolerability and consistency of effect of zolmitriptan nasal spray in a long-term migraine treatment trial. CNS Drugs 2003;17:839-51.